Sarah Geers represents pharmaceutical and biotechnology clients in intellectual property litigation in a variety of venues, including in district court, arbitration, and at the Patent Trial and Appeal Board (PTAB). Her practice spans Hatch-Waxman and other life science patent infringement actions, inter partes and post-grant review proceedings, and trade secret and misappropriation actions. Her litigation experience spans pre-suit preparation, discovery, trial, and appeal. Sarah is co-leader of Jones Day's PTAB area of focus.
Sarah recently achieved a victory on behalf of Merck in a bench trial of patent infringement actions against 16 generic defendants groups related to Bridion®, a first-in-class anesthesia reversal agent. She was also part of a team that helped Juno Therapeutics and Sloan Kettering win a more than $1.1 billion final award in a case in which the jury found that defendant Kite Pharma willfully infringed the asserted patent for cancer immunotherapy. Sarah has also been involved in the successful resolution of Hatch-Waxman litigation involving the transdermal patch Butrans®, as well as a plethora of patent infringement actions involving the pain medication OxyContin®.
Sarah is currently an adjunct professor at Seton Hall University School of Law, where she teaches a course on patent litigation.
Sarah was named a Law360 "Life Sciences Rising Star" in 2020. In 2023, she was named a "Next Generation Partner" in Patent Litigation by The Legal 500.
Before becoming a lawyer, Sarah worked as a research chemist at Merck & Co., where she was responsible for solid dosage form development and associated preformulation research.
執業經驗
- Seton Hall University (J.D. summa cum laude 2010; Order of the Coif; Comments Editor, Law Review); University of Minnesota (B.S. in Chemistry with high distinction and B.A. in Spanish Studies with high distinction 2003; Tau Beta Pi)
- New York, New Jersey, and registered to practice before the U.S. Patent and Trademark Office
- Conversational Spanish
*Before sending, please note:
*Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.